News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
SSY GROUP (02005.HK) Obtains Drug Production Registration Approvals for Multiple Products
SSY GROUP (02005.HK) announced that it has become the first domestic enterprise to obtain a drug production registration approval from the National Medical Products Administration ...
Reset
Send
The window will close in 5 seconds
SSY GROUP (02005.HK) Obtains Drug Production Registration Approvals for Multiple Products
Close
Recommend
2
Positive
1
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

SSY GROUP (02005.HK)  -0.020 (-0.844%)    Short selling $3.84M; Ratio 29.255%   announced that it has become the first domestic enterprise to obtain a drug production registration approval from the National Medical Products Administration for Fat-Soluble Vitamin Injection (I) (10ml), which is classified as a Category 3 chemical drug and deemed to have passed the consistency evaluation. The product is mainly used for children under 11 years old and infants as a supplement for intravenous nutrition to meet daily requirements of fat-soluble vitamins A, D2, E and K1.

In addition, the Group has obtained a drug production registration approval from the National Medical Products Administration for Metformin Hydrochloride Tablets (0.5g and 0.25g), which are classified as Category 4 chemical drugs and deemed to have passed the consistency evaluation. The products are mainly used for the treatment of Type 2 diabetes in cases where diet control and physical exercise alone fail to adequately control blood glucose levels.

Meanwhile, the Group has also obtained a drug production registration approval from the National Medical Products Administration for Doxazosin Mesylate Sustained-release Tablets (4mg), which are classified as Category 4 chemical drugs and deemed to have passed the consistency evaluation. The product is mainly used for symptomatic treatment of benign prostatic hyperplasia and for the treatment of hypertension. (ss/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-26 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.